☰

Mark C. Markowski, Ph.D. - Publications

Affiliations: 
2009 Tumor Biology Georgetown University, Washington, DC 
Area:
Cell Biology
Tree Info Grants Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Chen J, Zheng Q, Hicks JL, Trabzonlu L, Ozbek B, Jones T, Vaghasia AM, Larman TC, Wang R, Markowski MC, Denmeade SR, Pienta KJ, Hruban RH, Antonarakis ES, Gupta A, et al. MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Jci Insight. PMID 37971875 DOI: 10.1172/jci.insight.169868  0.373
2023 Chen J, Zheng Q, Hicks JL, Trabzonlu L, Ozbek B, Jones T, Vaghasia A, Larman TC, Wang R, Markowski MC, Denmeade SR, Pienta KJ, Hruban RH, Antonaraskis ES, Gupta A, et al. MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Biorxiv : the Preprint Server For Biology. PMID 36865273 DOI: 10.1101/2023.02.20.529259  0.373
2023 Mandl A, Markowski MC, Carducci MA, Antonarakis ES. Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert Opinion On Investigational Drugs. 1-16. PMID 36857796 DOI: 10.1080/13543784.2023.2186851  0.384
2022 Sena LA, Wang T, Wang H, Markowski MC, Antonarakis ES, Denmeade SR. Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 181: 23-25. PMID 36628897 DOI: 10.1016/j.ejca.2022.12.001  0.343
2022 Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201662. PMID 36367998 DOI: 10.1200/JCO.22.01662  0.375
2022 Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, ... ... Markowski MC, et al. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation. PMID 36194476 DOI: 10.1172/JCI162396  0.402
2022 Markowski MC, Wang H, De Marzo AM, Schweizer MT, Antonarakis ES, Denmeade SR. Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science. 41: 112-115. PMID 35677016 DOI: 10.1016/j.euros.2022.05.006  0.371
2022 Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, Steiner MS, Saltzstein DR, Eisenberger MA, Antonarakis ES. A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35416959 DOI: 10.1158/1078-0432.CCR-22-0162  0.337
2022 Denmeade S, Antonarakis ES, Markowski MC. Bipolar androgen therapy (BAT): A patient's guide. The Prostate. PMID 35357024 DOI: 10.1002/pros.24328  0.389
2022 Werner RA, Habacha B, Lütje S, Bundschuh L, Higuchi T, Hartrampf P, Serfling SE, Derlin T, Lapa C, Buck AK, Essler M, Pienta KJ, Eisenberger MA, Markowski MC, Shinehouse L, et al. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL. Molecular Imaging. 2022: 7056983. PMID 35283693 DOI: 10.1155/2022/7056983  0.341
2021 Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, Coffey M, Topiwala D, Gomes C, Ozbek B, Jones T, Rosen M, Dong L, Wiens S, Brennen WN, ... ... Markowski MC, et al. Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Research. PMID 34645612 DOI: 10.1158/0008-5472.CAN-20-3607  0.315
2021 Markowski MC, Kachhap S, De Marzo AM, Sena LA, Luo J, Denmeade SR, Antonarakis ES. Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer. PMID 34538582 DOI: 10.1016/j.clgc.2021.08.001  0.337
2021 Markowski MC, Sfanos KS. The interplay of microbiota and hormone regulation in men with prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34007013 DOI: 10.1038/s41391-021-00385-6  0.386
2021 Marshall CH, Chen Y, Kuo C, Cullen J, Jiang J, Rosner I, Markowski M, McLeod DG, Trock BJ, Eisenberger MA. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. The Journal of Urology. 101097JU000000000000. PMID 34003011 DOI: 10.1097/JU.0000000000001797  0.396
2021 Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, ... ... Markowski MC, et al. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002759. PMID 33617303 DOI: 10.1200/JCO.20.02759  0.352
2020 Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer (Oxford, England : 1990). 144: 302-309. PMID 33383350 DOI: 10.1016/j.ejca.2020.11.043  0.335
2020 Markowski MC, Antonarakis ES. Versus and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002246. PMID 32870734 DOI: 10.1200/JCO.20.02246  0.393
2020 Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, Teply BA, Ngomba N, Fu W, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Luo J, Antonarakis ES, et al. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology. PMID 32624280 DOI: 10.1016/J.Eururo.2020.06.042  0.356
2020 Antonarakis ES, Markowski MC. PARP inhibitors in prostate cancer: time to narrow patient selection? Expert Review of Anticancer Therapy. PMID 32521178 DOI: 10.1080/14737140.2020.1781622  0.372
2020 Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, Kiess AP, Dipasquale S, Huang J, Caldwell T, Leitzel J, Wendler D, Wang H, Thompson E, Powell J, ... ... Markowski M, et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). Bmc Cancer. 20: 492. PMID 32487038 DOI: 10.1186/S12885-020-07000-2  0.32
2020 Markowski MC, Sedhom R, Fu W, Gray JCR, Eisenberger MA, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. PSA and PSA Doubling Time Predict Findings on F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32250727 DOI: 10.1097/Ju.0000000000001064  0.366
2020 Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. The Prostate. PMID 31972048 DOI: 10.1002/Pros.23955  0.377
2019 Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, Carducci MA, Denmeade SR, Markowski MC, Isaacs WB, Antonarakis ES, Pritchard CC, Eisenberger MA, Lotan TL. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. Jco Precision Oncology. 3. PMID 31650100 DOI: 10.1200/PO.19.00081  0.315
2019 Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer. PMID 31530439 DOI: 10.1016/J.Clgc.2019.08.002  0.373
2019 Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, et al. Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology, Biology, Physics. PMID 31419509 DOI: 10.1016/J.Ijrobp.2019.08.008  0.354
2019 Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, et al. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). Bmc Cancer. 19: 572. PMID 31196032 DOI: 10.1186/S12885-019-5805-Z  0.32
2019 Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European Urology. PMID 31176623 DOI: 10.1016/J.Eururo.2019.05.032  0.349
2018 Markowski MC, Antonarakis ES. Germline genetic testing in prostate cancer - further enrichment in variant histologies? Oncoscience. 5: 62-64. PMID 29854870 DOI: 10.18632/oncoscience.403  0.343
2018 Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM. Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate. PMID 29851094 DOI: 10.1002/Pros.23657  0.399
2018 Ernst SE, Markowski MC, Gupta A, Wheelan SJ, Carter HB, Partin AW, Sears CL, Sfanos KS. Abstract 129: Biobanking and feasibility considerations for prostate cancer gastrointestinal microbiome studies Cancer Research. 78: 129-129. DOI: 10.1158/1538-7445.Am2018-129  0.425
2017 Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES. Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 2017. PMID 29170762  0.316
2017 Markowski MC, De Marzo AM, Antonarakis ES. BET inhibitors in metastatic prostate cancer: Therapeutic implications and rational drug combinations. Expert Opinion On Investigational Drugs. PMID 29032717 DOI: 10.1080/13543784.2017.1393518  0.386
2017 Markowski MC, Imus P, Wright JL, Schottenstein D, Paller CJ. Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report. Clinical Genitourinary Cancer. PMID 28325637 DOI: 10.1016/j.clgc.2017.02.001  0.34
2016 Markowski MC, Carducci MA. Early use of chemotherapy in metastatic prostate cancer. Cancer Treatment Reviews. PMID 27720577 DOI: 10.1016/j.ctrv.2016.09.017  0.311
2016 Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. The Prostate. PMID 27404039 DOI: 10.1002/Pros.23232  0.33
2016 Markowski MC, Wobker SE, Strowd RE, Antonarakis ES. Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer. Clinical Genitourinary Cancer. PMID 26992487 DOI: 10.1016/j.clgc.2016.02.001  0.373
2015 Markowski MC, Pienta KJ. Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. Asian Journal of Andrology. 17: 936-8; discussion 93. PMID 25865849 DOI: 10.4103/1008-682X.150843  0.336
2008 Markowski MC, Bowen C, Gelmann EP. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Research. 68: 6896-901. PMID 18757402 DOI: 10.1158/0008-5472.Can-08-0578  0.382
Show low-probability matches.